Clinical meaning
Long-acting beta-2 agonists (LABAs) are bronchodilators with a duration of action of 12 or more hours, used as maintenance therapy in asthma and COPD. The two principal LABAs are salmeterol (onset 30-60 minutes, duration 12 hours) and formoterol (rapid onset 5 minutes, duration 12 hours). Ultra-long-acting agents include vilanterol (24-hour duration, used in once-daily combination inhalers) and indacaterol (24-hour COPD agent).
LABAs bind to beta-2 adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase via Gs protein coupling, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light chain kinase (MLCK), reducing its affinity for the calcium-calmodulin complex. This prevents myosin-actin cross-bridge cycling, producing sustained smooth muscle relaxation and bronchodilation. LABAs also inhibit mast cell mediator release, reduce microvascular permeability, and enhance mucociliary clearance.
The critical safety concern is the FDA black box warning (subsequently modified in 2017) regarding LABA monotherapy in asthma. LABAs WITHOUT concurrent inhaled corticosteroids (ICS) were associated with increased risk of severe asthma exacerbations, hospitalizations, and asthma-related death in landmark studies (SMART trial, 2006). The mechanism of harm is hypothesized to involve: (1) masking of worsening airway inflammation by providing symptomatic bronchodilation without addressing the underlying inflammatory process; (2) beta-2 receptor desensitization (tachyphylaxis) with chronic stimulation, reducing the bronchodilator reserve available during acute exacerbations; (3) possible pro-inflammatory effects of unopposed beta-2 stimulation in the absence of corticosteroid-mediated anti-inflammatory control.